Schizophrenia is characterized by a wide spectrum of clinical manifestations, including strong effects on mood and behavior. Patients can also suffer from serious comorbidities including immune system or metabolic abnormalities. Recent advances using proteomic profiling approaches have increased our understanding of these molecular effects and have laid the groundwork for unraveling the heterogeneity of this broadly defined disease. These findings could lead to improved diagnosis and stratification of patients through identification of biochemically different disease subtypes and personalized medicine approaches. The inclusion of molecular signatures in psychiatry will be an important leap forward in providing more effective treatment of patients suffering from this debilitating disorder.

brain, comorbidities, inflammation, metabolic syndrome, personalized medicine, proteomics, schizophrenia, serum,
Biomarkers in Medicine
This work was funded by the European Commission 7th Framework Programme; grant id fp7/223427 - Developing minimally invasive, tools and technologies for high throughput, low cost molecular assays for the early diagnosis of schizophrenia and other psychiatric disorders (SCHIZDX)
Department of Neuroscience

Guest, P.C, Chan, M.K, Gottschalk, P.T, & Bahn, S. (2014). The use of proteomic biomarkers for improved diagnosis and stratification of schizophrenia patients. Biomarkers in Medicine (Vol. 8, pp. 15–27). doi:10.2217/bmm.13.83